Oct 1 |
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
|
Oct 1 |
Teva launches first U.S. generic against Novartis antidiarrheal Sandostatin LAR
|
Sep 30 |
Top Research Reports for Apple, Tesla & T-Mobile US
|
Sep 30 |
Novartis: Value Continues To Build With Double-Digit Percentage Growth Products
|
Sep 30 |
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
|
Sep 27 |
Volkswagen, Novartis could surprise in Q3 earnings season, UBS analysts warn
|
Sep 26 |
Novartis: Best Performing Big Pharma Of Past 6 Months Still Looks A Solid Long-Term Bet
|
Sep 25 |
Generate:Biomedicines and Novartis link on protein therapeutics development
|
Sep 24 |
Metsera touts long-acting GLP-1 drug; Novartis strikes an AI deal
|
Sep 21 |
Novartis' Pluvicto expected to dominate prostate cancer radiopharmaceutical market
|